ARTICLE | Company News
Sanofi said FDA issued a complete response letter to an NDA for Zynquista sotagliflozin as an adjunct to insulin for adults with Type I diabetes. The news sent shares of partner Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) down $1.74 (22%) to $6.20 on Friday.
Sanofi (Euronext:SAN; NASDAQ:SNY) and Lexicon said they will work with FDA to determine next steps...